Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 1—January 2021
Synopsis

Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan

Iacopo BaussanoComments to Author , Felix Sayinzoga, Ugyen Tshomo, Vanessa Tenet, Alex Vorsters, Daniëlle A.M. Heideman, Tarik Gheit, Massimo Tommasino, Marie Chantal Umulisa, Silvia Franceschi, and Gary M. Clifford
Author affiliations: International Agency for Research on Cancer, Lyon, France (I. Baussano, V. Tenet, T. Gheit, M. Tommasino, M.C. Umulisa, G.M. Clifford); Ministry of Health, Kigali, Rwanda (F. Sayinzoga); Jigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan (U. Tshomo); University of Antwerp, Antwerp, Belgium (A. Vorsters); Vrije Universiteit Amsterdam, Amsterdam, the Netherlands (D.A.M. Heideman); Centro di Riferimento Oncologico, Aviano, Italy (S. Franceschi)

Main Article

Figure 1

Timing of school-based human papillomavirus vaccination program and surveys in Rwanda (A) and Bhutan (B). Short dashed line represents routine vaccination. Long dashed line represents catch-up vaccination.

Figure 1. Timing of school-based human papillomavirus vaccination program and surveys in Rwanda (A) and Bhutan (B). Short dashed line represents routine vaccination. Long dashed line represents catch-up vaccination.

Main Article

Page created: November 03, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external